Pfizer and BioNTech Reports P-I/II Study Result of mRNA-Based Combination Vaccine Program Against Influenza and COVID-19
- The P-I/II study evaluating the safety, tolerability & immunogenicity of mRNA-based combination vaccine candidates in healthy adults aged 18-64yrs. with influenza & COVID-19
- The results showed robust immune responses to influenza A, influenza B, and SARS-CoV-2 strains while the mRNA-based vaccines showed their ability to induce robust Ab & T-cell responses. The safety profile was consistent with the COVID-19 vaccine, immunogenicity results showed point estimates for Geometric Mean Titer ratios
- The results will be published in a peer-reviewed journal & the P-III trial is expected to be initiated in the coming months. mRNA-based combination vaccine candidate received FTD from the US FDA for influenza & COVID-19
Ref: Pfizer | Image: Pfizer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at email@example.com
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.